Develops cell therapies for rare skin diseases and cancers.
Dec 2025Revenue $50.0K/yrExpenses $47.4M/yr
No trend
Figures by year
When will Inmune Bio be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was $50.0K and expenses $47.4M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $50.0K | $47.4M | −$47.4M |
| Dec 2024 | $14.0K | $42.6M | −$42.6M |
| Dec 2023 | $155K | $29.9M | −$29.7M |
| Dec 2022 | $374K | $26.3M | −$26.0M |
| Dec 2021 | $181K | $29.3M | −$29.2M |
| Dec 2020 | $11.0K | $12.2M | −$12.2M |
| Dec 2018 | $0.00 | $12.4M | −$12.4M |
| Dec 2017 | $0.00 | $981K | −$981K |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.